Skip to main content

Actionable Results
In About An Hour

We Use the Patient’s Immune System to Unlock a Rapid and Accurate Sepsis Diagnosis

identification of pathogens

About SeptiCyte®RAPID

SeptiCyte® was developed to empower clinicians to provide the most effective sepsis treatments, by using specific biomarkers in the patient’s immune system to measure dysregulated immune response signals that indicate sepsis. SeptiCyte® RAPID was FDA-cleared as a sepsis test by the U.S. FDA in November 2021.

Learn More About Our Technology

SeptiCyte® RAPID is a PCR-based test for sepsis designed to differentiate non-infectious systemic inflammatory response syndrome (SIRS) from sepsis in critically ill patients, providing an estimate of the likelihood of sepsis. This sepsis test uses a small volume of blood and can be performed easily in any hospital lab with the Biocartis Idylla™ platform. SeptiCyte® RAPID revolutionizes sepsis diagnosis and treatment, by providing actionable results within about an hour.

Explore Our Testing Platform
SeptiCyte host response results

Why SeptiCyte® RAPID for Sepsis Diagnosis

Sepsis can escalate quickly and fatally. Until now, blood tests for sepsis, based for example on microbiological culture, have been unreliable and slow. For hospitals in the U.S., diagnosing and treating patients with sepsis represents a service with high in-patient costs. By knowing whether sepsis is present, clinicians can initiate the most appropriate treatment as quickly as possible, including ICU admission when needed.

Understanding Sepsis

Sepsis can be a killer, resulting in organ failure and death. An early sepsis diagnosis, enabled by a fast sepsis test, can make the difference between life and death. Also, in cases where sepsis is not present, overuse of antibiotics can lead to new health problems, and to greater antibiotic resistance among vulnerable patient populations.

Advocacy Involvement

About Immunexpress

Immunexpress is a molecular diagnostic company developing technology to accurately rule-in or rule-out sepsis in patients suspected of infection. The company was founded with the exclusive purpose of developing and commercializing SeptiCyte® technology for sepsis diagnosis. Immunexpress is a privately-owned with offices in Seattle, USA, and Brisbane, Australia.

Immunexpress’ PCR based genetic testing products are based on patented host immune response technologies validated in large human clinical trials around the globe.

SeptiCyte® RAPID is an FDA-cleared and CE Marked sepsis diagnostic test that combines SeptiCyte® technology with the Biocartis’ Idylla™ platform, giving physicians an estimate of sepsis likelihood in one hour. Immunexpress has a commercialization partnership with Biocartis in Europe.

Immunexpress is committed to improving outcomes for patients suspected of sepsis. Our goal is to transform sepsis diagnostics by providing the technology to rapidly enable clinicians to confidently make the right sepsis treatment decisions.